Several medtech VCs back commercialization of EOS Ultra Low Dose 2D/3D Xray
PARIS & ATLANTA--(BUSINESS WIRE)--biospace med, the orthopaedic imaging company, announced today the closing of $18 million (12 m€) in venture capital financing led by NBGI Ventures (London) and Crédit Agricole Private Equity (Paris). Edmond de Rothschild Investment Partners (Paris) and UFG PE (Paris), current investors in the company, also have subscribed to the current round of financing. Aelios Finance served as financial advisor to biospace med.
Infusion of new capital from these venture funds, combined with their strong expertise in the medtech industry, will allow the worldwide market expansion of EOS ultra low dose 2D/3D Xray.
“This is a quantum leap in technology for the orthopaedic and imaging communities, which have been waiting for a solution to address their specific needs,” said Marie Meynadier, biospace med president and CEO. “This new round of financing will accelerate the worldwide commercial deployment of EOS, which already is installed in several European countries and Canada. With the recent FDA approval to market EOS in the United States, this financing package will accelerate our market penetration there as well.”
EOS captures a whole or partial body image in a single scan without the need for any digital stitching – all at a reduced dose. In addition, the system allows simultaneous bi-plane image acquisition (frontal and lateral). Information submitted to FDA in support of biospace med’s marketing application demonstrated up to 10 times reduction in dose when compared with commercially available film systems – without compromising image quality. EOS can also generate a 3D skeletal reconstruction from the two simultaneously acquired planar images. This product will also feature automatic measurement software designed to calculate a variety of length and angle calculations between individual bones and joints, potentially helping to evaluate global balance and posture.
EOS is based upon a patented particle detector technology, for which Georges Charpak received the Nobel Prize in Physics. Along with Charpak, Dr. Jean Dubousset, a world-renowned French pediatric orthopaedic surgeon, and Dr. Gabriel Kalifa, professor and chairman of radiology at Saint Vincent de Paul Hospital, Paris, assisted in the design of EOS.
“I am delighted to see that the technology I developed is now routinely used in patient care centers to the benefit of the patients and the medical community,” notes Georges Charpak, founder of biospace med.
“We are impressed about biospace med’s focused value proposition, and are convinced the company’s innovative technology and leadership team will make a strong impact in the medical imaging market.” said Christian Sarwa, investment manager at NBGI.
“biospace med has remarkable potential to take a leadership position in the $2 billion imaging market, and we are thrilled to support accelerated market penetration through our investment,” said Alexia Perouse, director at Crédit Agricole Private Equity.
“biospace med’s management has delivered on their commitment to bring innovation to the orthopaedic sector, which is why we have invested in the company since 2005,” said Raphaël Wisniewski, investment director at EdRIP.
“Our new subscription reflects our continued confidence in biospace med’s outstanding potential,” added Olivier Denigot, investment director at UFG PE.